Role of Microbiota in post liver transplant patients
Not Applicable
- Conditions
- Health Condition 1: K70-K77- Diseases of liver
- Registration Number
- CTRI/2022/10/046327
- Lead Sponsor
- Amrita Institute Of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Adult patients with ACLF being planned for liver transplant who fall within the EASL CLIF SOFA definition.
Exclusion Criteria
1. Patients with other diseases of the gut eg: Inflammatory bowel disease.
2. Patients with malignancies other than Hepatocellular carcinoma
3. Patients with recent intake of synbiotics within last 1 month
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method To assess the role of synbiotics in patients with ACLF undergoing LDLT (Live Donor Liver Transplantation). <br/ ><br>Timepoint: Following Infectious complications within 6 months will be assessed. <br/ ><br>Blood stream infection: clinical signs of infection with a positive bacterial culture <br/ ><br>Urinary tract infection: positive urine culture with or without dysuria <br/ ><br>Intra-abdominal infection: positive drain cultures or positive cultures from per-cutaneously drained intra-abdominal collections. <br/ ><br>Respiratory infection: positive broncho alveolar lavage cultures <br/ ><br>
- Secondary Outcome Measures
Name Time Method Adverse reactions due to synbiotics <br/ ><br>Timepoint: Throughout study period;morbidity and mortlityTimepoint: Throughout the study;qualitative and quantitative change in microbiota <br/ ><br>Timepoint: 0 and at 6 week